A phase 1 clinical trial is still recruiting participants, but the study is expected to be completed by December 2024. Other considerations: An injectable version of DMAU is also being studied. In general, before the FDA considers approving any medication for use, it needs to go through phase 3 clinical trials. Status: Researchers have completed a phase 1 clinical trial for oral DMAU, but there hasn’t been much movement on a phase 2 clinical trial. But if approved, it’d likely be taken daily over time - similar to oral birth control pills used by women. So far, studies have only assessed its safety over a 1-month time period. How it’s used: DMAU is an oral pill that’s given once daily. It’s a hormonal medication that suppresses certain male sex hormones to reduce sperm counts while you’re taking it. What it is: Dimethandrolone undecanoate ( DMAU) is a medication that’s being studied as a male birth control pill. You can read more about this announcement here. The results from the upcoming studies in people could be similar to - or very different from - these findings. Keep in mind: Findings from animal studies are often different from results obtained from human studies. With this positive data in mind, researchers are planning on starting human studies later this year.
And once the mice stopped taking YCT529, they were able to have pups (babies) again about a month later. Researchers from the American Chemical Society recently presented study results that showed YCT529 was up to 99% effective at stopping pregnancies in mice by reducing sperm counts. Latest news Animal study finds that YCT529 is ‘up to 99% effective’ at preventing pregnancy in mice If it continues to advance through clinical trials, it’ll be given a more traditional drug name. Other considerations: YCT529 is a preliminary, chemical name for this potential medication. Researchers are hoping to start human clinical trials in the second half of 2022. These results were positive, so now YCT529 is set to be studied in people. Status: Early results from studies in mice were announced by the American Chemical Society in March 2022. At this time, we don’t have much other information about how it’ll be dosed. How it’s used: YCT529 is being studied as a once-daily oral pill. It’s thought to reduce sperm counts by attaching to a special receptor (chemical binding site) in your body for vitamin A. What it is: YCT529 is a chemical that’s being developed as a non-hormonal male birth control pill. Here, we’ll summarize the latest updates for male birth control medications in development. To help address this demand, a number of medications are actively being researched in clinical studies. These advances have impacted the lives of millions, but there’s still a lot of interest in finding a successful and well-tolerated male birth control option. Birth control pills, intrauterine devices ( IUDs), long-acting implants, and many others have all won FDA approval. If you’re having vaginal sex and want to use contraception, an external condom or a vasectomy are still your two options to choose from.īy comparison, many contraceptive options are now available for women. But as time has pushed forward, progress in research and development hasn’t followed suit. The idea of male birth control has been floating around for decades.
0 kommentar(er)
